Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19: Azelastine Nasal Spray to Reduce Symptoms and Hospitalization
2021-006485-20Phase 3Terminated
- Sponsor
- URSAPHARM
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of azelastine in coronavirus disease 2019 (COVID-19), sponsored by URSAPHARM. Primary endpoint: Proportion of sustained recovery from COVID-19-related symptoms. Started Dec 2022; status: terminated.
02
Drugs
azelastine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-006485-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006485-20.